T2 Biosystems (NASDAQ:TTOO) Coverage Initiated by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of T2 Biosystems (NASDAQ:TTOO) in a research note issued on Monday. The brokerage set a “sell” rating on the medical equipment provider’s stock.

Separately, Canaccord Genuity Group boosted their price objective on T2 Biosystems from $3.00 to $5.00 and gave the company a “hold” rating in a report on Tuesday, July 30th.

T2 Biosystems Trading Down 1.0 %

TTOO stock opened at $0.49 on Monday. T2 Biosystems has a 12-month low of $0.42 and a 12-month high of $8.38. The business’s fifty day moving average price is $1.24 and its 200 day moving average price is $3.35.

Institutional Investors Weigh In On T2 Biosystems

An institutional investor recently raised its position in T2 Biosystems stock. Virtu Financial LLC boosted its stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOO) by 29.9% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,096 shares of the medical equipment provider’s stock after purchasing an additional 3,018 shares during the quarter. Virtu Financial LLC owned approximately 0.24% of T2 Biosystems worth $39,000 as of its most recent SEC filing. Institutional investors and hedge funds own 23.18% of the company’s stock.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.